更多开发者作品
The Lancet Gastroenterology & Hepatology
| 1. | [Articles] VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study | Man-Fung Yuen, Young-Suk Lim, Ki Tae Yoon, Tien-Huey Lim, Jeong Heo, Pisit Tangkijvanich, Won Young Tak, Vaidehi Thanawala, Daniel Cloutier, Shenghua Mao, Andre Arizpe, Andrea L Cathcart, Sneha V Gupta, Carey Hwang, Edward Gane | |
| 2. | [Comment] Does siRNA-based therapy require pegylated interferon-alfa-2a to cure HBV infection? | Fabien Zoulim | |
| 3. | [Corrections] Correction to Lancet Gastroenterol Hepatol 2024; published online Sept 17. https://doi.org/10.1016/S2468-1253(24)00222-X | | |
| 4. | [Articles] Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study | Mathias Jachs, Aitor Odriozola, Fanny Turon, Lucile Moga, Luis Téllez, Petra Fischer, Dario Saltini, Wilhelmus J Kwanten, Maria Grasso, Elba Llop, Yuly P Mendoza, Angelo Armandi, Julia Thalhammer, Carlos Pardo, Antonio Colecchia, Federico Ravaioli, Benjamin Maasoumy, Wim Laleman, José Presa, Jörn M Schattenberg, Annalisa Berzigotti, José L Calleja, Vincenza Calvaruso, Sven Francque, Filippo Schepis, Bogdan Procopet, Agustín Albillos, Pierre-Emmanuel Rautou, Juan C García-Pagán, Ángela Puente, José I Fortea, Thomas Reiberger, Mattias Mandorfer, SSM-100Hz/ACLD Study Group, Baveno Cooperation | |
| 5. | [Comment] Spleen stiffness in portal hypertension algorithms: the next advance | Cristina Rigamonti | |
| 6. | [Review] Disorders of gastric motility | Andrea Shin | |
| 7. | [Articles] Harms with placebo in trials of biological therapies and small molecules as induction therapy in inflammatory bowel disease: a systematic review and meta-analysis | Shahida Din, Jonathan Segal, Jonathan Blackwell, Beatriz Gros, Christopher J Black, Alexander C Ford | |
| 8. | [Comment] Do placebos harm patients in IBD trials? | Fernando Gomollón | |
| 9. | [Articles] Harms with placebo in trials of biological therapies and small molecules as maintenance therapy in inflammatory bowel disease: a systematic review and meta-analysis | Beatriz Gros, Jonathan Blackwell, Jonathan Segal, Christopher J Black, Alexander C Ford, Shahida Din | |
| 10. | [Comment] Availability of point-of-care HBV tests in resource-limited settings | Daryl T Y Lau, Kathy Jackson, Camila A Picchio, Anna Kramvis, Mark Sonderup, Maud Lemoine, Gail Matthews, Jessica Howell, Carla S Coffin, Margaret Hellard, Alice U Lee, David A Anderson, Helene A Kerth, El Eunyoung Lee, John E Tavis, Maura Dandri, Peter A Revill, C Wendy Spearman, Capucine Penicaud, Massimo Levrero, Manal El-Sayed, ICE-HBV POC Model in Resource Limited Settings working group | |
| 11. | [Articles] Computer-aided diagnosis for the resect-and-discard strategy for colorectal polyps: a systematic review and meta-analysis | Cesare Hassan, Tommy Rizkala, Yuichi Mori, Marco Spadaccini, Masashi Misawa, Giulio Antonelli, Emanuele Rondonotti, Evelien Dekker, Britt B S L Houwen, Oliver Pech, Sebastian Baumer, James Weiquan Li, Daniel von Renteln, Claire Haumesser, Roberta Maselli, Antonio Facciorusso, Loredana Correale, Maddalena Menini, Alessandro Schilirò, Kareem Khalaf, Harsh Patel, Dhruvil K Radadiya, Pradeep Bhandari, Shin-ei Kudo, Shahnaz Sultan, Per Olav Vandvik, Prateek Sharma, Douglas K Rex, Farid Foroutan, Alessandro Repici, CADx analysis study group | |
| 12. | [Comment] Is computer-aided diagnosis living up to its promise? | Quirine E W van der Zander | |
| 13. | [Comment] Lifting the minority tax in gastroenterology and hepatology | Sophie M Balzora | |
| 14. | [Comment] Global differences in the management of alcohol-associated hepatitis | Hanna Blaney, Luis Antonio Díaz, Nhi Li, Gurpreet Malhi, Rokhsana Mortuza, Xiaolong Qi, Anand V Kulkarni, Ramon Bataller, Joaquin Cabezas, Alexandre Louvet, Elliot B Tapper, Juan Pablo Arab | |
| 15. | [Articles] Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium | Zhujun Cao, Florence Wong, Ashok K Choudhury, Patrick S Kamath, Mark Topazian, Aldo Torre, Peter C Hayes, Jacob George, Ramazan Idilman, Wai-Kay Seto, Hailemichael Desalegn, Mario Reis Alvares-da-Silva, Brian J Bush, Leroy R Thacker, Qing Xie, Jasmohan S Bajaj, CLEARED Consortium | |
| 16. | [Comment] Regional disparities of infections in cirrhosis: a call for action | Nipun Verma, Salvatore Piano | |
| 17. | [Comment] Best buy interventions to address the burden of steatotic liver disease | Jeffrey V Lazarus, Henry E Mark, Naim Alkhouri, Luis Antonio Díaz, Ajay Duseja, C Wendy Spearman, Maja Thiele, Vincent Wai-Sun Wong, Zobair M Younossi | |
| 18. | [Articles] Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial | Matthew C Choy, Christopher F D Li Wai Suen, Danny Con, Kristy Boyd, Raquel Pena, Kathryn Burrell, Ourania Rosella, David Proud, Richard Brouwer, Alexandra Gorelik, Danny Liew, William R Connell, Emily K Wright, Kirstin M Taylor, Aviv Pudipeddi, Michelle Sawers, Britt Christensen, Watson Ng, Jakob Begun, Graham Radford-Smith, Mayur Garg, Neal Martin, Daniel R van Langenberg, Nik S Ding, Lauren Beswick, Rupert W Leong, Miles P Sparrow, Peter De Cruz | |
| 19. | [Comment] Infliximab rescue therapy in acute severe ulcerative colitis: more does not equal better | Saurabh Kedia, Vineet Ahuja | |
更新于 47 分钟前
近期历史最近 100 条记录
| 2024-10-08 | [Articles] VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study | Man-Fung Yuen, Young-Suk Lim, Ki Tae Yoon, Tien-Huey Lim, Jeong Heo, Pisit Tangkijvanich, Won Young Tak, Vaidehi Thanawala, Daniel Cloutier, Shenghua Mao, Andre Arizpe, Andrea L Cathcart, Sneha V Gupta, Carey Hwang, Edward Gane | |
| 2024-10-08 | [Comment] Does siRNA-based therapy require pegylated interferon-alfa-2a to cure HBV infection? | Fabien Zoulim | |
| 2024-09-26 | [Corrections] Correction to Lancet Gastroenterol Hepatol 2024; published online Sept 17. https://doi.org/10.1016/S2468-1253(24)00222-X | | |
| 2024-09-24 | [Articles] Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling st | Mathias Jachs, Aitor Odriozola, Fanny Turon, Lucile Moga, Luis Téllez, Petra Fischer, Dario Saltini, Wilhelmus J Kwanten, Maria Grasso, Elba Llop, Yuly P Mendoza, Angelo Armandi, Julia Thalhammer, Carlos Pardo, Antonio Colecchia, Federico Ravaioli, Benjam | |
| 2024-09-24 | [Comment] Spleen stiffness in portal hypertension algorithms: the next advance | Cristina Rigamonti | |
| 2024-09-21 | [Review] Disorders of gastric motility | Andrea Shin | |
| 2024-09-20 | [Articles] Harms with placebo in trials of biological therapies and small molecules as induction therapy in inflammatory bowel disease: a systematic review and meta-analysis | Shahida Din, Jonathan Segal, Jonathan Blackwell, Beatriz Gros, Christopher J Black, Alexander C Ford | |
| 2024-09-20 | [Comment] Do placebos harm patients in IBD trials? | Fernando Gomollón | |
| 2024-09-20 | [Articles] Harms with placebo in trials of biological therapies and small molecules as maintenance therapy in inflammatory bowel disease: a systematic review and meta-analysis | Beatriz Gros, Jonathan Blackwell, Jonathan Segal, Christopher J Black, Alexander C Ford, Shahida Din | |
| 2024-09-19 | [Comment] Availability of point-of-care HBV tests in resource-limited settings | Daryl T Y Lau, Kathy Jackson, Camila A Picchio, Anna Kramvis, Mark Sonderup, Maud Lemoine, Gail Matthews, Jessica Howell, Carla S Coffin, Margaret Hellard, Alice U Lee, David A Anderson, Helene A Kerth, El Eunyoung Lee, John E Tavis, Maura Dandri, Peter A | |
| 2024-09-18 | [Articles] Computer-aided diagnosis for the resect-and-discard strategy for colorectal polyps: a systematic review and meta-analysis | Cesare Hassan, Tommy Rizkala, Yuichi Mori, Marco Spadaccini, Masashi Misawa, Giulio Antonelli, Emanuele Rondonotti, Evelien Dekker, Britt B S L Houwen, Oliver Pech, Sebastian Baumer, James Weiquan Li, Daniel von Renteln, Claire Haumesser, Roberta Maselli, | |
| 2024-09-18 | [Comment] Is computer-aided diagnosis living up to its promise? | Quirine E W van der Zander | |
| 2024-09-14 | [Comment] Lifting the minority tax in gastroenterology and hepatology | Sophie M Balzora | |
| 2024-09-11 | [Comment] Global differences in the management of alcohol-associated hepatitis | Hanna Blaney, Luis Antonio Díaz, Nhi Li, Gurpreet Malhi, Rokhsana Mortuza, Xiaolong Qi, Anand V Kulkarni, Ramon Bataller, Joaquin Cabezas, Alexandre Louvet, Elliot B Tapper, Juan Pablo Arab | |
| 2024-09-05 | [Articles] Global prevalence and characteristics of infections and clinical outcomes in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium | Zhujun Cao, Florence Wong, Ashok K Choudhury, Patrick S Kamath, Mark Topazian, Aldo Torre, Peter C Hayes, Jacob George, Ramazan Idilman, Wai-Kay Seto, Hailemichael Desalegn, Mario Reis Alvares-da-Silva, Brian J Bush, Leroy R Thacker, Qing Xie, Jasmohan S | |
| 2024-09-05 | [Comment] Regional disparities of infections in cirrhosis: a call for action | Nipun Verma, Salvatore Piano | |
| 2024-09-04 | [Comment] Best buy interventions to address the burden of steatotic liver disease | Jeffrey V Lazarus, Henry E Mark, Naim Alkhouri, Luis Antonio Díaz, Ajay Duseja, C Wendy Spearman, Maja Thiele, Vincent Wai-Sun Wong, Zobair M Younossi | |
| 2024-09-03 | [Articles] Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial | Matthew C Choy, Christopher F D Li Wai Suen, Danny Con, Kristy Boyd, Raquel Pena, Kathryn Burrell, Ourania Rosella, David Proud, Richard Brouwer, Alexandra Gorelik, Danny Liew, William R Connell, Emily K Wright, Kirstin M Taylor, Aviv Pudipeddi, Michelle | |
| 2024-09-03 | [Comment] Infliximab rescue therapy in acute severe ulcerative colitis: more does not equal better | Saurabh Kedia, Vineet Ahuja | |
| 2024-08-17 | [Articles] Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial | Klara Dorman, Stefan Boeck, Karel Caca, Maximilian Reichert, Thomas J Ettrich, Helmut Oettle, Oliver Waidmann, Dominik P Modest, Lothar Müller, Patrick Michl, Stephan Kanzler, Daniel Pink, Anke Reinacher-Schick, Michael Geißler, Henning Pelz, Volker Kunzm | |
| 2024-08-17 | [Comment] Metastatic pancreatic cancer: a new standardised dose-reduction regimen? | Paula Ghaneh, Daniel Palmer | |
| 2024-08-15 | [Articles] Polyp detection with colonoscopy assisted by the GI Genius artificial intelligence endoscopy module compared with standard colonoscopy in routine colonoscopy practice (COLO-DETECT): a multicentre, open-label, parallel-arm, pragmatic randomised | Alexander Seager, Linda Sharp, Laura J Neilson, Andrew Brand, James S Hampton, Tom J W Lee, Rachel Evans, Luke Vale, John Whelpton, Nathania Bestwick, Colin J Rees, COLO-DETECT trial team | |
| 2024-08-14 | [Articles] Indocyanine green near-infrared fluorescence bowel perfusion assessment to prevent anastomotic leakage in minimally invasive colorectal surgery (AVOID): a multicentre, randomised, controlled, phase 3 trial | Robin A Faber, Ruben P J Meijer, Daphne H M Droogh, Jasmijn J Jongbloed, Okker D Bijlstra, Fran Boersma, Jeffrey P B M Braak, Elma Meershoek-Klein Kranenbarg, Hein Putter, Fabian A Holman, J Sven D Mieog, Peter A Neijenhuis, Esther van Staveren, Johanne G | |
| 2024-08-14 | [Comment] The promise of indocyanine green in colorectal surgery | Zoe Garoufalia | |
| 2024-08-01 | [Personal View] Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions | Ryan J Jalleh, Chris K Rayner, Trygve Hausken, Karen L Jones, Michael Camilleri, Michael Horowitz | |
| 2024-07-31 | [Comment] The need for affordable, pragmatic, investigator-led clinical trials of treatment strategies in inflammatory bowel disease | Nurulamin M Noor, Shaji Sebastian, Miles Parkes, Tim Raine | |
| 2024-07-26 | [Editorial] Viral hepatitis: time for action | The Lancet Gastroenterology & Hepatology | |
| 2024-07-20 | [Articles] Long-term effects of once-only flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: 21-year follow-up of the UK Flexible Sigmoidoscopy Screening randomised controlled trial | Kate Wooldrage, Emma C Robbins, Stephen W Duffy, Amanda J Cross | |
| 2024-07-20 | [Comment] Brief sigmoidoscopy provides 21-year colorectal cancer risk reduction in men | Michael Bretthauer, Nastazja D Pilonis | |
| 2024-07-19 | [Articles] An artificial intelligence-assisted system versus white light endoscopy alone for adenoma detection in individuals with Lynch syndrome (TIMELY): an international, multicentre, randomised controlled trial | Oswaldo Ortiz, Maria Daca-Alvarez, Liseth Rivero-Sanchez, Antonio Z Gimeno-Garcia, Marta Carrillo-Palau, Victoria Alvarez, Alejandro Ledo-Rodriguez, Luigi Ricciardiello, Chiera Pierantoni, Robert Hüneburg, Jacob Nattermann, Raf Bisschops, Sabine Tejpar, A | |
| 2024-07-19 | [Comment] Artificial intelligence-assisted adenoma detection in people with Lynch syndrome | Carol A Burke, Carole Macaron, Aparajita Singh | |
| 2024-07-18 | [Articles] Trends and levels of the global, regional, and national burden of appendicitis between 1990 and 2021: findings from the Global Burden of Disease Study 2021 | GBD 2021 Appendicitis Collaborator Group | |
| 2024-07-17 | [News] Hepatitis C epidemic among Rohingya refugees in Cox's Bazar: a public health emergency | Udani Samarasekera | |
| 2024-07-16 | [Articles] Effect of mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease on postoperative endoscopic recurrence (SPICY): an international, randomised controlled trial | Eline M L van der Does de Willebois, Vittoria Bellato, Marjolijn Duijvestein, Jarmila D W van der Bilt, Koen van Dongen, Antonino Spinelli, Geert R D'Haens, Marco W Mundt, Federica Furfaro, Silvio Danese, Andrea Vignali, Willem A Bemelman, Christianne J B | |
| 2024-07-16 | [Comment] Targeting the mesentery with surgery in ileocolic Crohn's disease: where do we stand? | Benjamin Click, Stefan D Holubar | |
| 2024-07-10 | [Review] Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies | Laure Elkrief, Virginia Hernandez-Gea, Marco Senzolo, Agustin Albillos, Anna Baiges, Annalisa Berzigotti, Christophe Bureau, Sarwa Darwish Murad, Andrea De Gottardi, François Durand, Juan-Carlos Garcia-Pagan, Ton Lisman, Mattias Mandorfer, Valérie McLin, | |
| 2024-06-26 | [Comment] Breaking down barriers between liver, addiction, and mental health services for people with alcohol-related liver disease | Ashwin D Dhanda, Victoria Allgar, Neeraj Bhala, Lynne Callaghan, Joana Castro, Shilpa Chokshi, Amanda Clements, Colin Drummond, Ewan H Forrest, Lesle Manning, Richard Parker, Debbie L Shawcross, Jennifer Towey | |
| 2024-06-19 | [Articles] Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, doubl | Yoon-Koo Kang, Masanori Terashima, Young-Woo Kim, Narikazu Boku, Hyun Cheol Chung, Jen-Shi Chen, Jiafu Ji, Ta-Sen Yeh, Li-Tzong Chen, Min-Hee Ryu, Jong Gwang Kim, Takeshi Omori, Sun Young Rha, Tae Yong Kim, Keun Won Ryu, Shinichi Sakuramoto, Yasunori Nish | |
| 2024-06-19 | [Comment] Immune-checkpoint blockade in surgical management of gastric or gastro-oesophageal junction adenocarcinoma | Maeve A Lowery | |
| 2024-06-18 | [Articles] Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study | Harry L A Janssen, Young-Suk Lim, Pietro Lampertico, Jeong Heo, Chi-Yi Chen, Claire Fournier, Tak Yin Owen Tsang, Ho Bae, Chien-Hung Chen, Carla S Coffin, Sang Hoon Ahn, Huy Trinh, John F Flaherty, Frida Abramov, Yang Zhao, Yang Liu, Audrey Lau, Polina Ge | |
| 2024-06-18 | [Comment] Broadening clinical indications of tenofovir alafenamide in chronic hepatitis B | Lung-Yi Mak | |
| 2024-06-14 | [Editorial] No accident: the UK infected blood scandal | The Lancet Gastroenterology & Hepatology | |
| 2024-06-13 | [Review] Clinical management of liver cyst infections: an international, modified Delphi-based clinical decision framework | Renée Duijzer, Lucas H P Bernts, Anja Geerts, Bart van Hoek, Minneke J Coenraad, Chantal Rovers, Domenico Alvaro, Ed J Kuijper, Frederik Nevens, Jan Halbritter, Jordi Colmenero, Juozas Kupcinskas, Mahdi Salih, Marie C Hogan, Maxime Ronot, Valerie Vilgrain | |
| 2024-06-11 | [Articles] Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open- | Arndt Vogel, Anna Saborowski, Patrick Wenzel, Henning Wege, Gunnar Folprecht, Albrecht Kretzschmar, Philipp Schütt, Lutz Jacobasch, Nicolas Ziegenhagen, Stefan Boeck, Danmei Zhang, Stephan Kanzler, Sebastian Belle, Johannes Mohm, Eray Gökkurt, Christian L | |
| 2024-06-11 | [Comment] Nanoliposomal irinotecan in advanced biliary tract cancers | David Malka, Raphaël Colle | |
| 2024-05-30 | [Comment] Considerations for treating autistic individuals in gastroenterology clinics | Timothy Buie, Kara Margolis | |
| 2024-05-30 | [Articles] Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study | Do-Youn Oh, Aiwu Ruth He, Mohamed Bouattour, Takuji Okusaka, Shukui Qin, Li-Tzong Chen, Masayuki Kitano, Choong-kun Lee, Jin Won Kim, Ming-Huang Chen, Thatthan Suksombooncharoen, Masafumi Ikeda, Myung Ah Lee, Jen-Shi Chen, Piotr Potemski, Howard A Burris, | |
| 2024-05-30 | [Comment] Immunotherapy in biliary tract cancer: are we finally on the right path? | Angela Dalia Ricci, Alessandro Rizzo, Claudio Lotesoriere | |
| 2024-05-16 | [Articles] Duration of risk reduction in colorectal cancer incidence and mortality after a complete colonoscopy in Ontario, Canada: a population-based cohort study | Arlinda Ruco, Rahim Moineddin, Rinku Sutradhar, Jill Tinmouth, Qing Li, Linda Rabeneck, M Elisabetta Del Giudice, Catherine Dubé, Nancy N Baxter | |
| 2024-05-16 | [Comment] Negative screening colonoscopy and long-term colorectal cancer risk—is it time to extend the screening interval? | J E G IJspeert, M E van Leerdam | |
| 2024-05-15 | [Review] Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease | Marietta Iacucci, Giovanni Santacroce, Irene Zammarchi, Yasuharu Maeda, Rocío Del Amor, Pablo Meseguer, Bisi Bode Kolawole, Ujwala Chaudhari, Antonio Di Sabatino, Silvio Danese, Yuichi Mori, Enrico Grisan, Valery Naranjo, Subrata Ghosh | |
| 2024-05-14 | [Review] Infections in cirrhosis | Salvatore Piano, Chalermrat Bunchorntavakul, Sebastian Marciano, K Rajender Reddy | |
| 2024-05-09 | [Articles] Clinical significance of combined tumour-infiltrating lymphocytes and microsatellite instability status in colorectal cancer: a systematic review and network meta-analysis | Durgesh Wankhede, Tanwei Yuan, Matthias Kloor, Niels Halama, Hermann Brenner, Michael Hoffmeister | |
| 2024-05-09 | [Comment] Rethinking colorectal cancer prognosis: beyond microsatellite status | Elisabetta Fenocchio | |
| 2024-05-07 | [Articles] Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial | Alexander G Miethke, Adib Moukarzel, Gilda Porta, Joshue Covarrubias Esquer, Piotr Czubkowski, Felipe Ordonez, Antonella Mosca, Amal A Aqul, Robert H Squires, Etienne Sokal, Daniel D'Agostino, Ulrich Baumann, Lorenzo D'Antiga, Nagraj Kasi, Nolwenn Laborde | |
| 2024-04-30 | [News] Scottish Parliament votes to increase minimum unit price for alcohol | Udani Samarasekera | |
| 2024-04-30 | [Review] Targeting the EGFR signalling pathway in metastatic colorectal cancer | Stefania Napolitano, Giulia Martini, Davide Ciardiello, Sara Del Tufo, Erika Martinelli, Teresa Troiani, Fortunato Ciardiello | |
| 2024-04-24 | [Articles] Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial | Nadia Ovchinsky, Madeleine Aumar, Alastair Baker, Ulrich Baumann, Philip Bufler, Mara Cananzi, Piotr Czubkowski, Özlem Durmaz, Ryan Fischer, Giuseppe Indolfi, Wikrom W Karnsakul, Florence Lacaille, Way S Lee, Giuseppe Maggiore, Philip Rosenthal, Mathias R | |
| 2024-04-24 | [Editorial] Urgent action needed to achieve viral hepatitis elimination | The Lancet Gastroenterology & Hepatology | |
| 2024-04-19 | [Articles] A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised controlled trial | Sanna Nybacka, Hans Törnblom, Axel Josefsson, Johann P Hreinsson, Lena Böhn, Åsa Frändemark, Cecilia Weznaver, Stine Störsrud, Magnus Simrén | |
| 2024-04-19 | [Comment] Managing irritable bowel syndrome: balancing diet and pharmacotherapy | Uday C Ghoshal, Uzma Mustafa, Mahesh K Goenka | |
| 2024-04-18 | [Review] Pathophysiology and therapeutic options for cirrhotic portal hypertension | Sergi Guixé-Muntet, Sergio Quesada-Vázquez, Jordi Gracia-Sancho | |
| 2024-04-17 | [Articles] Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study | Neil Chanchlani, Simeng Lin, Claire Bewshea, Benjamin Hamilton, Amanda Thomas, Rebecca Smith, Christopher Roberts, Maria Bishara, Rachel Nice, Charlie W Lees, Shaji Sebastian, Peter M Irving, Richard K Russell, Timothy J McDonald, James R Goodhand, Tariq | |
| 2024-04-17 | [Comment] PANTS extension study: how best to use anti-TNF drugs in Crohn's disease | Gareth C Parkes, Charlotte R H Hedin | |
| 2024-04-11 | [Comment] WHO 2024 hepatitis B guidelines: an opportunity to transform care | Philippa J Easterbrook, Niklas Luhmann, Sahar Bajis, Myat Sandi Min, Morkor Newman, Olufunmilayo Lesi, Meg C Doherty | |
| 2024-04-06 | [Articles] Hepatocellular carcinoma surveillance among people living with hepatitis B in Senegal (SEN-B): insights from a prospective cohort study | Adrià Ramírez Mena, Mbaye Thiam, Daye Ka, Ibrahima Niang, Judicaël Tine, Louise Fortes, Kiné Ndiaye, Ousseynou Ndiaye, Maguette Fall, Assietou Gaye, Ndeye Fatou Ngom, Fatou Fall, Annalisa Berzigotti, Gregory Dale Kirk, Antoine Jaquet, Moussa Seydi, Gilles | |
| 2024-04-06 | [Comment] Liver cancer surveillance in people with hepatitis B in Africa | Dennis A Ndububa | |
| 2024-03-28 | [Review] Ecogastroenterology: cultivating sustainable clinical excellence in an environmentally conscious landscape | Kassem Sharif, Enrique Rodriguez de Santiago, Paula David, Arnon Afek, Ian M Gralnek, Shomron Ben-Horin, Adi Lahat | |
匿名用户只展示最新 100 条榜单历史，更多历史数据请登录后查看，支持时光机按天筛选
Sponsors
